Long-Term Efficacy of Bivalent HPV Vaccine

Vaccine against HPV-16/18 remained highly effective for more than 6 years after administration.

Questions about duration of protective immunity abound during vaccine development, but the need for boosters often cannot be determined until sufficient time has elapsed in the vaccinated group. In an extended follow-up study sponsored by the manufacturer of the bivalent human papillomavirus (HPV) vaccine (Cervarix), investigators assessed outcomes in 776 participants for as long as 6.4 years.

The vaccine retained 95% efficacy against new HPV-16/18 infections and 100% efficacy against persistent HPV-16/18 infections as well as against cervical intraepithelial neoplasia (CIN) 1+ or 2+ associated with HPV-16/18. Notably, the vaccine also showed 60% efficacy against HPV-31 and 78% efficacy against HPV-45 (HPV types that were not included in the…

Reviewing Author

Anna Wald, MD, MPH

Disclosures

Consultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)

RoyaltiesUpToDate

Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris

Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases

Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)